BRIC nations identified as emerging leaders in global clinical trials landscape

Despite challenges, increasing health care budgets and advancing markets in BRIC (Brazil, Russia, India and China) nations create significant opportunities for clinical trials, according to a new report from Thomson Reuters.

Released today, the report, Overcoming Clinical Challenges in BRIC Markets, explores the benefits and challenges of conducting clinical trials in the pharmaceutical markets of the BRIC countries.

The recent study utilized Cortellis Clinical Trials Intelligence, a unique platform that integrates content from multiple sources to assess the clinical trial landscape. It found that while increased regulations, evolving clinical standards, and complex pipelines have driven some sponsors out of the BRIC nations, a rise in rank for each country is expected over the next four years, indicating blossoming healthcare budgets and markets that are ripe with opportunities for development.

Each BRIC country has its own challenges and attractions